GlobeNewsWire
18 Mar 2026, 23:34 UTC · 28w ago
Verdict
Headline takes no side. We score PCVX +1.00 — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company announced unprecedented positive Phase 1/2 results and the advancement of VAX-31 into a comprehensive Phase 3 program.
More negative than 68% of ticker scores this week
Vaxcyte's VAX-31 candidate demonstrated superior immune responses for 11 serotypes and potential for broader coverage than Prevnar 20.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 73% of relationship scores this week
[mutual] Vaxcyte's VAX-31 vaccine is being compared head-to-head against MSD's Capvaxive (PCV21) in Phase 3 trials.
More positive than 73% of relationship scores this week
[mutual] Vaxcyte's VAX-31 vaccine is being compared head-to-head against Pfizer's Prevnar 20 (PCV20) as a competing pneumococcal conjugate vaccine.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
CNBC
1h ago
+36.0%
Price agrees with the score
$73.82 vs $54.28 close before publication (Mar 18) · not market-adjusted
PCVX chart →
